Evaluation of Drug–Drug Interactions of Rucaparib and CYP1A2, CYP2C9, CYP2C19, CYP3A, and P‐gp Substrates in Patients With an Advanced Solid Tumor

This phase I study (CO‐338‐044; NCT02740712), conducted in patients with advanced solid tumors, evaluated the effect of the poly(ADP‐ribose) polymerase (PARP) inhibitor rucaparib on the pharmacokinetics (PK) of caffeine 200 mg, warfarin 10 mg, omeprazole 40 mg, and midazolam 2 mg (cytochrome P450 (C...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiao, Jim J., Nowak, Dorota, Ramlau, Rodryg, Tomaszewska‐Kiecana, Monika, Wysocki, Piotr J., Isaacson, Jeff, Beltman, Jeri, Nash, Eileen, Kaczanowski, Robert, Arold, Gerhard, Watkins, Simon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6342242/
https://www.ncbi.nlm.nih.gov/pubmed/30427584
http://dx.doi.org/10.1111/cts.12600

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6342242/
https://www.ncbi.nlm.nih.gov/pubmed/30427584
http://dx.doi.org/10.1111/cts.12600

Ejemplares similares